SYNLOGIC, INC. (SYBX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.14

From 52W high−34.97%

Volume32203.00

Market cap$14.66M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.14

From 52W high

−34.97%

Volume

32203.00

Market cap

$14.66M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

54.0

MomentumView details →

1D Return

+2.59%

YTD Return

+5.36%

SummaryUpdated Jun 1, 2026

Synlogic, Inc. (NASDAQ:SYBX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. The company went public in September 2015 and focuses on developing synthetic biotic medicines, which are engineered microorganisms designed to treat metabolic and immunological diseases. Synlogic represents a novel approach in biotechnology, using genetically modified bacteria as therapeutic agents rather than traditional small molecule drugs or biologics.

Ask drillr about SYNLOGIC, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−5.45%

ROA (TTM)

−4.86%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+38.06%

FCF YoY

−19.53%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+95.83%

EBITDA YoY

—

MomentumView details →

1D Return

+2.59%

YTD Return

+5.36%

1Y Return

−33.71%

RSI (14)

54.0

vs 50D SMA

+10.67%

vs 200D SMA

+41.72%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.19x

Quick Ratio

9.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

—

Beats (12Q)

5/12

Next Q EPS Est

−$5.80

Avg Surprise (4Q)

41.97%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−655000.00

Op. CF (TTM)

−3.84M

Next earningsNov 11, 2026 →

Latest newsMore news →

Caldera Therapeutics entered into a definitive merger agreement for an all-stock merger with Synlogic, becoming wholly owned subsidiaries of a new holding company, and the combined company will operate as Caldera Therapeutics, Inc. and list on Nasdaq under ticker CALD.53d ago

Similar companies

Vyome Holdings, Inc.HIND Moleculin Biotech, Inc.MBRX Adial Pharmaceuticals, Inc.ADIL Quoin Pharmaceuticals, Ltd.QNRX Daré Bioscience, Inc.DARE Enlivex Therapeutics Ltd.ENLV Find similar companies →

Latest newsMore news →